












































Key words: 急性移植片対宿主病（acute graft-versus-host disease），









体であるTNF-α receptor ₁ が移植後に上昇するとその後
のGVHDの発症予知と重症度の良い指標となること₂ ），







腸 管 GVHD に 特 異 的 な regenerating islet-derived ₃ -α
（REG ₃ α），GVHD治療抵抗性のバイオマーカーとして












































（ ₁）抗原提示細胞の活性化，（ ₂）ドナーT 細胞の活性化，（ ₃）臓器障害．APC: antigen 





































oxygenase- ₁ ; HO- ₁ ）とヘモグロビンスカベンジャー受
容体であるCD₁₆₃を紹介する．これらは，いずれもマク
ロファージおけるヘム鉄の代謝に重要な蛋白であり，血











































例，骨髄異形成症候群 ₄ 例，悪性リンパ腫 ₄ 例，多発性
骨髄腫 ₁ 例，再生不良性貧血 ₁ 例）を対象として，前処
置前（pre-conditioning; pre），移植日（day ₀ ），移植後₁₄
日（day₁₄），₂₁日（day₂₁），₂₈日（day₂₈）の各ポイント
において血清中のフェリチン，HO- ₁ ，sCD₁₆₃を測定し
た．HO- ₁ と sCD₁₆₃はELISAを用いて測定した（HO- ₁  
図 ₂　 マクロファージにおけるヘム代謝経路 （CD₁₆₃-HO- ₁ -フェリチン産生経路）






















pre ₁₀₈₂ ng/mL（±₆₇₇），day ₀  ₁₆₀₁（±₁₃₅₆），day₁₄ 
₁₉₆₇（±₉₉₅），day₂₁ ₃₃₄₀（±₁₇₉₁），day₂₈ ₃₀₅₇（±
₁₇₃₄），HO- ₁ 平均値は，pre ₃．₇₄ ng/mL（±₂．₄₄），day ₀  
₄．₅₂（±₂．₇₀），day₁₄ ₅．₁₇（±₃．₃₃），day₂₁ ₆．₃₇（±
₃．₀₅），day₂₈ ₅．₆₆（±₃．₃₁），sCD₁₆₃平均値は，pre ₆₅₃ 




の解析では，フェリチンとHO- ₁ の相関係数 r = ₀．₅₀₃（p 
< ₀．₀₀₀₁），フェリチンとsCD₁₆₃ r = ₀．₆₁₉（p < ₀．₀₀₀₁），





いずれも有意差を認めなかった（no GVHD vs. GVHD: フェ
リチン ₂₈₇₉ vs. ₃₉₇₇ ng/mL，p = ₀．₀₉₂₃，HO- ₁  ₅．₉₁ vs. 
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ASSOCIATION BETWEEN ACUTE GVHD AND MACROPHAGE ACTIVATION  
IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Takuya Miyazaki
Department of Hematology and Clinical Immunology,  
Yokohama City University Graduate School of Medicine
　Graft-versus-host disease (GVHD) is the major transplant-related complication after hematopoietic stem cell 
transplantation, but reaching a definite diagnosis or obtaining good treatment response for GVHD are often difficult. 
Acute GVHD, seen in the early phase of transplantation, is initiated by host-reactive donor T cells, but a variety of 
immune reactions are associated with the pathogenesis. Although macrophage activation after transplantation has 
been suggested to play an important role in the pathogenesis of acute GVHD, the mechanisms and clinical 
implications remain unclear. Herein, I summarize previous advances in GVHD diagnosis, pathogenesis, and 
biomarkers for the diagnosis and prognosis of acute GVHD. Furthermore, I focus on the association between acute 
GVHD and macrophage activation in transplantation and introduce our ongoing clinical study. Finally, I discuss the 
clinical impact of macrophage activation on transplant-related complications, including acute GVHD.
host disease. Lancet, 373: ₁₅₅₀－₁₅₆₁, ₂₀₀₉.
₇ ） Mosser DM, Edwards JP: Exploring the full spectrum of 
macrophage activation. Nat Rev Immunol, 8 : ₉₅₈－₉₆₉, 
₂₀₀₈.
₈ ） Yachie A: Heme oxygenase and its role in defense system; 
paradigm shift of anti-inflammatory therapy. Nihon 
Rinsho Meneki Gakkai Kaishi, 30: ₁₁－₂₁, ₂₀₀₇.
₉ ） Miyazaki T, Kirino Y, Takeno M, et al: Serum HO- ₁  is 
useful to make differential diagnosis of secondary 
hemophagocyt ic  syndrome f rom other  s imi lar 
hematological conditions. Int J Hematol, 91: ₂₂₉－₂₃₇, 
₂₀₁₀.
₁₀） Baeten D, Møller HJ, Delanghe J, Veys EM, Moestrup SK, 
De Keyser F: Association of CD₁₆₃+ macrophages and 
local production of soluble CD₁₆₃ with decreased 
lymphocyte activation in spondylarthropathy synovitis. 
Arthritis Rheum, 50: ₁₆₁₁－₁₆₂₃, ₂₀₀₄.

